Bayer AG's Second Quarter Financial Results Show Significant Challenges

In a recent announcement, Bayer AG revealed a 3.6% annual decline in its second-quarter sales for the fiscal year 2025, totaling €10.7 billion. The pharmaceutical giant also reported a net loss of €199 million, a stark contrast to the €34 million loss recorded in the same period the previous year. Additionally, losses per share escalated from €0.03 to €0.20.

First Half Performance and Future Outlook

The first half of the year saw Bayer's sales decrease by 1.7% compared to 2024, amounting to €24.5 billion. Net income and earnings per share (EPS) both experienced a 44% drop, settling at €1.1 billion and €1.12, respectively.

Despite these challenges, CEO Bill Anderson remains optimistic, stating, "We affirm our objective to significantly contain the litigation risk by the end of 2026." He also highlighted the operational success of the Pharma business and positive developments in the pipeline and launch assets.